Information Provided By: 
Fly News Breaks for August 15, 2019
MDCO
Aug 15, 2019 | 08:09 EDT
Jefferies analyst Biren Amin sees a low prospect of failure for The Medicines Co.'s upcoming Orion Phase III trials. It is unlikely that the LDL benefit will deteriorate in the trial, Amin tells investors in a research note. The analyst also expects a "clean safety profile" that mirrors the marketed PCSK9 drugs. The likelihood of "good" data looks high, with potential share upside of 20%-25%, says the analyst. He keeps a Buy rating The Medicines Co. with a $44 price target.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
